The IBA Cyclone® KIUBE 300 has the highest production capacity ever reached with a PET cyclotron with a production of up to 300 FDG* doses in two hours.
Louvain-la-Neuve, Belgium, June 21st 2018 - IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of solutions for the diagnosis and treatment of cancer, announces it will deliver three new Cyclone® KIUBE units in its higher power configuration, 300μA, in Saudi Arabia, the Netherlands and America.
Since launch in 2016, IBA has sold more than 25 Cyclone®
KIUBE units and has established the Cyclone®
KIUBE as the mid-energy cyclotron of choice due to its power and compact size. UZ Brussel, a hospital in Belgium, recently reported excellent production results from its Cyclone®
KIUBE 300 (more info)
The Cyclone® KIUBE is available in four configurations: 100μA, 150μA, 180μA and 300μA – granting users considerable production flexibility. Users can start with the Cyclone® KIUBE 100 while maintaining the ability to increase their PET Center’s capacity over time, allowing them to benefit from the cyclotron’s best-in-class technology and meet the increasing demand for FDG*.
“The IBA Cyclone® KIUBE 300 is the first compact industrial mid-energy cyclotron capable of such performances,” said Dr Muhammad Sarfaraz Mirza, Business Line Manager at Attieh Medico in Saudi Arabia. “It will allow us to reach higher levels of production while retaining the flexibility to alter our FDG production, as well as granting us the capacity to produce a large portfolio of non-conventional radioisotopes.”
“We have been using IBA cyclotrons since 1997. The cyclotrons demonstrate market leading reliability and the customer support we receive from IBA is excellent,” said Erik Van Lier, Managing Director BV Cyclotron VU, Amsterdam, the Netherlands. “It was therefore an obvious choice to purchase two new Cyclone® KIUBE cyclotrons, 180μA and 300μA, considering their outstanding performance and technology.”
IBA RadioPharma Solutions will be exhibiting at the upcoming SNMMI 2018 Annual Meeting (Society of Nuclear Medicine and Molecular Imaging) in Philadelphia, Pennsylvania, June 23–26, 2018 at booth #548. Attend the Cyclone®
KIUBE 300 poster presentation
on June 24, 4pm room 103C.
*fluorodeoxyglucose labelled with F-18 is the most commonly used radiotracer in positron emission molecular imaging.